ORX-750 is under clinical development by Centessa Pharmaceuticals and currently in Phase II for Type 1 Narcolepsy (Narcolepsy with Cataplexy). According to GlobalData, Phase II drugs for Type 1 Narcolepsy (Narcolepsy with Cataplexy) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ORX-750 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ORX-750 overview
ORX-750 is under development for the treatment of narcolepsy type I, narcolepsy type 2, idiopathic hypersomnia (IH) and other sleep disorders. These are administered through oral route. They act by targeting orexin OX2 receptor. It is being developed based on StaR technology.
Centessa Pharmaceuticals overview
Centessa Pharmaceuticals is a next-generation biopharmaceutical firm aiming to reinvent the medication development process. The company is headquartered in Cambridge, England, the UK.
For a complete picture of ORX-750’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
